In two recent glioma studies, both PCC0208009 (PCC), a potent IDO enzyme inhibitor with an IC50 of 4.52 nM, and RY103, an IDO-TDO dual inhibitor, have demonstrated suppression of tumor cell line- and intra-tumoral-IDO expression, respectively (112, 115). Here, IDO1 is linked to glioma.